The purpose of this study is to learn what happens to nemtabrutinib in a person's body when given to participants with severe kidney disease and to healthy participants.
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
All participants:
Participants with Severe Renal impairment (RI):
Healthy volunteers:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Renal Impairment Participants:
Healthy Matched Control Participants:
All participants will receive a single oral dose of nemtabrutinib on Day 1.
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016)
A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017)
A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)
A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)